Cargando…
Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway
BACKGROUND: Betahistine is a clinical medication for the treatment of benign paroxysmal positional vertigo (BPPV). Otolin, a secreted glycoprotein with a C-terminal globular domain homologous to the immune complement C1q, has been identified as a biomarker for BPPV. However, the role of complement C...
Autores principales: | Hui, Jing, Lei, Qi, Ji, Zhi, Zi, Dingjing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981858/ https://www.ncbi.nlm.nih.gov/pubmed/35379352 http://dx.doi.org/10.1186/s40659-022-00385-3 |
Ejemplares similares
-
Benign Paroxysmal Positional Vertigo (BPPV) in COVID-19
por: Picciotti, Pasqualina Maria, et al.
Publicado: (2021) -
Characteristics of assessment and treatment in Benign Paroxysmal Positional Vertigo (BPPV)
por: Power, Laura, et al.
Publicado: (2020) -
Relationship between benign paroxysmal positional vertigo (BPPV) and sleep quality
por: Iranfar, Khosrow, et al.
Publicado: (2022) -
Benign Paroxysmal Positional Vertigo (BPPV): History,
Pathophysiology, Office Treatment and Future Directions
por: Hornibrook, Jeremy
Publicado: (2011) -
Curing Benign Paroxysmal Positional Vertigo (BPPV) Through Telehealth: A Case Series
por: Bashir, Khalid, et al.
Publicado: (2021)